Related Experiment Video

Updated: Jun 18, 2026

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles
09:27

An Emerging Target Paradigm to Evoke Fast Visuomotor Responses on Human Upper Limb Muscles

Published on: August 25, 2020

Other new targets

Helen J Mackay1, Amit M Oza

  • 1Princess Margaret Hospital, University of Toronto, 610 University Ave., Toronto, Ontario, Canada. Helen.Mackay@uhn.on.ca

International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|December 4, 2009
PubMed

Insights

New targeted therapies offer hope for advanced epithelial ovarian cancer. This review explores novel agents and biomarkers, emphasizing personalized medicine approaches to improve patient outcomes.

Area of Science:

  • Oncology
  • Translational Medicine
  • Clinical Trials

Background:

  • Advanced epithelial ovarian cancer (EOC) outcomes remain poor despite surgical and diagnostic improvements.
  • Cancer biology advancements have spurred numerous clinical trials for targeted agents in EOC.
  • Antiangiogenic agents have been prominent, but other novel targets are emerging.

Purpose of the Study:

  • To review newer targeted therapy approaches for epithelial ovarian cancer.
  • To highlight the significance of clinical trial design in evaluating novel agents.
  • To emphasize the role of biomarkers in advancing personalized medicine for EOC.

Main Methods:

  • Review of recent clinical trials and scientific literature on targeted therapies for EOC.
  • Focus on novel targets and agents beyond antiangiogenic therapies.
  • Analysis of the importance of trial design and biomarker incorporation.

Main Results:

  • Several novel targeted agents and therapeutic strategies are under investigation for EOC.
  • The integration of biomarkers is crucial for identifying patient populations likely to benefit from targeted therapies.
  • Optimized trial designs are essential for effectively evaluating these new treatments.

Conclusions:

  • Personalized medicine, driven by targeted therapies and biomarkers, represents the future for advanced EOC treatment.
  • Continued research and well-designed clinical trials are necessary to translate these advancements into improved patient outcomes.
  • The field is moving towards tailored treatment strategies based on individual tumor biology.

More Related Videos

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library08:40

Genome-wide Screen for miRNA Targets Using the MISSION Target ID Library

Published on: April 6, 2012

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization03:08

Using Human Differentially Expressed Gene Lists to Perform Downstream Pathway Enrichment Analysis and Target Prioritization

Published on: October 3, 2025

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...